ESKD in IgAN
Reducing Risk of Transplantation for People with IgA Nephropathy: What Managed Care Pharmacists Can Do to Help Optimize Treatment
Speakers: Michelle Richardson, PharmD, Assistant Professor of MedicineRosanna Coppo, MD, FERA, Nephrologist and Chair
Duration: 60 minutes
Presented on: February 21, 2023
Michelle Richardson, PharmD
Michelle Richardson, PharmD
Assistant Professor of MedicineMichelle Richardson, PharmD, is a member of the Special and Scientific Staff in the William B. Schwartz Division of Nephrology at Tufts Medical Center and an Assistant Professor of Medicine at Tufts University School of Medicine. She has over 20 years of experience in medication management in patients with CKD and those treated with dialysis. Dr. Richardson is the co-chair of a Kidney Health Initiative on using patient-reported outcomes in patients treated with dialysis experiencing muscle cramping and an invited member of the international KDIGO Controversies Conference on Symptom-based Complications in Dialysis. She is an experienced clinical pharmacist, researcher, and educator that translates patient-reported outcome measures into clinical care of individual patients and populations.
Rosanna Coppo, MD, FERA
Rosanna Coppo, MD, FERA
Nephrologist and ChairRosanna Coppo, MD, FERA, is a nephrologist and chair of the Regina Margherita Children’s University Hospital for 25 years. She is an expert in glomerular diseases, particularly in IgAN; she has authored or co-authored approximately 140 publications dealing with the pathogenesis, progression, and treatment of IgAN. Dr. Coppo has launched and coordinated the VALIGA study investigating 1147 patients, both children and adults, with IgAN from 13 European countries. She is member of the Steering Committee of the International IgAN Network Research Group and a scientific advisor for several companies developing new drugs for IgAN. Dr. Coppo’s clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies.
CME InformationReducing Risk of Transplantation for People with IgA Nephropathy: What Managed Care Pharmacists Can Do to Help Optimize TreatmentThis activity for ACCME credit is jointly provided by Global Education Group and PlatformQ Health Education, LLC.
This activity for ACPE credit is jointly provided by the Academy of Managed Care Pharmacy and PlatformQ Health Education, LLC.
In collaboration with Kidney Disease: Improving Global Outcomes (KDIGO).
ACKNOWLEDGEMENTThis activity is supported by an educational grant from Travere Therapeutics.
DATE OF ENDURING ACTIVITYThis activity was released on February 21, 2023 and is valid for 12 months. Requests for credit must be made no later than February 21, 2024.
TARGET AUDIENCEThe educational design of this activity addresses the needs managed care pharmacists and other clinicians who make managed-care decisions related to the treatment of kidney failure in IgAN.
STATEMENT OF NEED/PROGRAM OVERVIEWBecause it is “silent” or asymptomatic, patients with immunoglobulin-A nephropathy (IgAN) often experience diagnostic delay. A common cause of kidney failure that can necessitate kidney transplantation, IgAN can also recur after transplantation, leading to allograft failure. People with IgAN suffer from heightened pain and fatigue, as well as negative impacts on quality of life (QoL) and mental health.
Several targeted treatment options with improved efficacy and safety compared to current care have recently been or are being developed. These therapies are poised to address unmet needs and reduce risk of transplantation.
Join an expert nephrologist and pharmacist to discuss these new and emerging treatment options, up-to-date evidence on their safety and efficacy, and recommendations from practice guidelines. Managed care pharmacists will be prepared to enhance access to these beneficial treatments and include them in medication-management programs for appropriate patients with IgAN.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Describe the burden of IgAN and the inability of current treatment approaches to reduce risk of transplantation
- Summarize data supporting the efficacy and safety of dual inhibition of RAS and endothelin-1 to reduce proteinuria and slow kidney-function decline in those with IgAN more than RAS inhibition alone does
- Recognize the place of dual inhibitors of RAS and endothelin-1 to treat IgAN, delay risk of transplantation, and reduce overall cost of care
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Type of activity: Knowledge-based
Contact hour(s): 1
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
SUCCESSFUL COMPLETION AND INSTRUCTIONS TO RECEIVE CREDIT
FOR PHYSICIANSIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
FOR PHARMACISTSParticipants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented on February 21, 2023. CPE credit will be reported directly to CPE Monitor within 60 days of participation.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPSGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Rosanna Coppo, MD, FERA
Fondazione Ricerca Molinette
Past Director Nephrology, Dialysis and Transplantation. Regina Margherita Children Hospital, Turin, Italy
International IgA Nephropathy Network Research Group Steering Committee
Consulting Fee (e.g., Advisory Board): Alnylam, Amgen, argenyx, Bayer, Calliditas, Chinook, Menarini, Novartis, Purespring, Otsuka-Visterra, Reata, Stadapharm, Travere Michelle M. Richardson, PharmD
Special and Scientific Staff
William B. Schwartz Division of Nephrology
Tufts Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Nothing to disclose Malkia White
Kidney Health Advocate and Transplant Recipient
Consulting Fee (e.g., Advisory Board): Alexion Pharmaceuticals, Inc.
The planners and managers at Academy of Managed Care Pharmacy have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMERParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Physician Accreditation Support:For information about the physician accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Pharmacist Accreditation Support:For information about the pharmacist accreditation of this program, please contact AMCP at 703-684-2600 or email@example.com.
Technical Support:For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.